Last reviewed · How we verify

NCT05866380

Early Identification of Heart Failure in a High-Risk Diabetic Cohort

Active, enrolled Last updated 15 April 2025
What this trial tests

trial testing heart failure risk factors in Type2diabetes in 3,500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
23 March 2022
Primary endpoint
1 March 2025
31 May 2025

Quick facts

Lead sponsorMackay Memorial Hospital
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment3,500
Start date23 March 2022
Primary completion1 March 2025
Estimated completion31 May 2025
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Mackay Memorial Hospital

Who can join

Adults 20 to 100, any sex, with Type2diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Type 2 diabetes is an important co-morbid condition strongly associated with the risk of developing heart failure (HF). Risk scores such as the WATCH-DM score that predict the occurrence of HF among diabetes patients are largely based on data collected from white ethnicities. Here, the investigators sought to investigate surrogate markers for predicting HF among type 2 diabetes patients of Asian ethnicities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type2diabetes

Currently open trials in the same condition.

Other Mackay Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05866380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing